Pathology

Pathology is the conceptual spine of the NEET PG and INI-CET examinations. It is the bridge subject that converts the "why" of Physiology and Biochemistry into the "what goes wrong" of clinical Medicine, Surgery, Obstetrics and the rest of the clinical disciplines. Almost no clinical question can be answered confidently without a working pathology vocabulary — and the exam knows it. A candidate who has mastered Pathology rarely struggles with image-based, "next-best-investigation" or "most likely diagnosis" stems, because the answer is usually a morphological or mechanistic fact wearing clinical clothes.

This page is a mother overview of the entire subject as tested in current Indian PG entrance exams. It walks system by system through the high-yield core, the classic associations examiners love, the numerical criteria you must memorise, the traps that cost rank, the overlaps with other subjects, and a realistic study and revision roadmap. Treat it as the map; the individual modules are the territory.

---

How Pathology Is Tested

Weightage and format

In the NEET PG pattern (200 MCQs, single best answer, negative marking), Pathology directly contributes roughly 22–28 questions — comfortably among the top three highest-yield subjects alongside Medicine and Pharmacology. When you add the indirect contribution (the pathology embedded inside Medicine, Surgery, OBG and Paediatrics stems), the practical footprint of pathology reasoning is closer to 35–40 questions. In INI-CET (AIIMS/PGIMER pattern, 200 MCQs, often more concept- and image-heavy), Pathology is proportionally even more rewarding because the paper rewards the candidate who understands mechanism rather than the one who has merely memorised drug doses.

General Pathology and Haematology together account for the single largest slice — frequently half of all pure pathology questions — so they deserve disproportionate attention. Neoplasia (tumour markers, immunohistochemistry, grading/staging, hallmarks of cancer) is the fastest-growing high-yield zone and overlaps heavily with the systemic chapters.

Recurring question styles

• Image-based stems. Gross specimens (e.g., "wedge-shaped pale infarct"), peripheral smears (schistocytes, Auer rods, smudge cells, target cells), histology slides (Reed–Sternberg cell, signet-ring cell, Aschoff body), and special stains (Congo red apple-green birefringence, PAS, Prussian blue). Even when no image is shown, the description is a verbal image — learn to recognise the buzzwords.
• "Most specific marker / most sensitive marker." Tumour markers, autoantibodies, immunohistochemistry (IHC) panels.
• Mechanism / "which mediator." Inflammation chemical mediators, apoptosis pathways, cell-injury cascades.
• Numerical criteria. Anaemia cut-offs, RDW, transudate vs exudate (Light's criteria), Duke criteria, RIFLE/AKIN for renal injury.
• Single best association. Disease ↔ gene, disease ↔ deposit, disease ↔ inheritance, syndrome ↔ tumour.
• Assertion–reason and multi-statement items (more in INI-CET): test whether you can spot a half-true distractor.

The exam consistently rewards the classic / textbook association over the rare exception. When in doubt between a textbook answer and an "edge case," the textbook answer is statistically correct.

---

General Pathology

This is the foundation and the highest-yielding group. Examiners return to the same handful of themes every year.

Cell injury, adaptation and death

• Reversible vs irreversible injury. The hallmark of irreversibility is mitochondrial permeability transition and severe membrane damage; the earliest morphological sign of reversible injury is cellular (hydropic) swelling, driven by failure of the Na⁺/K⁺-ATPase pump.
• Apoptosis vs necrosis. Apoptosis is energy-dependent, no inflammation, with caspase activation. Intrinsic (mitochondrial, BCL-2 family, cytochrome-c → APAF-1 → caspase-9) vs extrinsic (death receptor, Fas–FasL, caspase-8). Know p53 as the guardian that triggers apoptosis on irreparable DNA damage.
• Types of necrosis are perennial: coagulative (most solid organ infarcts), liquefactive (brain, abscess), caseous (TB), fat (pancreatitis, saponification), fibrinoid (vasculitis, malignant hypertension), gangrenous (limbs).
• Cellular adaptations: hypertrophy, hyperplasia, atrophy, metaplasia. Barrett oesophagus (squamous → columnar) is the classic exam metaplasia and a premalignant trap.
• Intracellular accumulations and pigments: lipofuscin (wear-and-tear), haemosiderin (Prussian blue positive), and free radical injury (lipid peroxidation, antioxidants: SOD, glutathione peroxidase, catalase, vitamins A/C/E).

Trap: Students confuse "fatty change" (reversible accumulation) with necrosis. Fatty change is an accumulation, not cell death.

Inflammation and repair

• Acute inflammation mediators. Vasodilation → histamine, prostaglandins, NO. Pain → bradykinin, PGE₂. Fever → IL-1, IL-6, TNF, PGE₂. The most potent chemotactic agents recur: C5a, LTB₄, IL-8 (CXCL8), bacterial products.
• Cell of chronic inflammation: macrophage; granuloma = epithelioid macrophages, with IFN-γ as the key cytokine driving macrophage activation and TNF maintaining the granuloma (hence reactivation TB on anti-TNF therapy — a classic integration with Pharmacology).
• Wound healing: primary vs secondary intention; the strongest determinant of healing is vitamin C (collagen cross-linking via prolyl/lysyl hydroxylase) and adequate oxygenation. Type III collagen is laid early and replaced by type I (granulation → scar). Keloid = excess type III collagen beyond wound margin.

Trap: "Labile vs stable vs permanent cells" — neurons and cardiac myocytes are permanent (do not regenerate), hence scar after MI and infarct.

Haemodynamic disorders, thrombosis, shock

• Virchow's triad: endothelial injury, stasis, hypercoagulability.
• Lines of Zahn indicate antemortem thrombus.
• Embolism: fat embolism (long-bone fracture, 24–72 h), amniotic fluid embolism, air embolism, paradoxical embolism (via PFO).
• Infarct colours: red (haemorrhagic — lung, intestine, loose tissue, dual blood supply) vs pale/white (solid organs — heart, kidney, spleen).
• Shock types and progression (non-progressive → progressive → irreversible); DIC — consumption of platelets and factors, schistocytes, raised D-dimer, prolonged PT/aPTT, low fibrinogen.

Immunopathology (high-yield, image-poor, concept-rich)

• Hypersensitivity reactions I–IV with prototypes. Type IV (delayed, T-cell) includes contact dermatitis, TB granuloma, transplant rejection.
• Autoantibodies (heavily overlapped with Medicine): anti-dsDNA & anti-Sm (SLE, specific), anti-histone (drug-induced lupus), anti-centromere (limited scleroderma/CREST), anti-Scl-70 (diffuse scleroderma), anti-Jo-1 (polymyositis), anti-mitochondrial (PBC), c-ANCA/PR3 (GPA), p-ANCA/MPO (microscopic polyangiitis, EGPA).
• Amyloidosis: Congo red → apple-green birefringence under polarised light; AL (light chain, plasma cell dyscrasia) vs AA (chronic inflammation, SAA precursor); β₂-microglobulin in dialysis; transthyretin in senile/familial.

---

Haematology

The second pillar — and arguably the most question-dense per page. Peripheral smear morphology is examined relentlessly.

Anaemias

Anaemia	MCV	Key clue / morphology	Diagnostic test
Iron deficiency	Low (microcytic, hypochromic)	Pencil cells, target cells; ↑RDW, ↓ferritin, ↑TIBC	Serum ferritin (most specific)
Thalassaemia	Low	Target cells, basophilic stippling; normal/↑RDW low	HbA₂ ↑ (β-thal); HPLC
Sideroblastic	Low/Normal	Ring sideroblasts (Prussian blue)	Bone marrow iron stain
Megaloblastic (B12/folate)	High	Hypersegmented neutrophils, oval macrocytes	Serum B12/folate, ↑homocysteine; methylmalonic acid ↑ in B12 only
Aplastic	Normal	Pancytopenia, hypocellular fatty marrow	Bone marrow biopsy

Traps:

• B12 deficiency raises both methylmalonic acid and homocysteine; folate deficiency raises homocysteine only. This single fact distinguishes them and is a recurring INI-CET item.
• Ferritin is an acute-phase reactant — it can be normal/high in iron deficiency complicated by inflammation; then look at TIBC/transferrin saturation.
• Don't confuse RDW: high in iron deficiency, typically normal/low in thalassaemia trait (uniformly small cells).

Haemolytic anaemias

• Hereditary spherocytosis: spherocytes, ↑MCHC, abnormal osmotic fragility (EMA binding test is the modern confirmatory), spectrin/ankyrin defect; spherocytes also in warm AIHA.
• G6PD deficiency: bite cells, Heinz bodies, X-linked, oxidative stress trigger (fava beans, primaquine, infection).
• Sickle cell: HbS, Glu→Val at position 6 of β-chain; sickled cells, Howell–Jolly bodies (autosplenectomy).
• PNH: CD55/CD59 deficiency (GPI anchor, PIGA mutation), confirmed by flow cytometry/FLAER; thrombosis is the main killer.
• Microangiopathic (MAHA): schistocytes — DIC, TTP (ADAMTS13 deficiency), HUS (Shiga toxin, EHEC O157:H7).

Leukaemias and lymphomas

Entity	Buzzword / marker	Association
AML	Auer rods, MPO+; M3/APL → t(15;17), DIC, treat with ATRA	Faggot cells
ALL	TdT+, most common childhood leukaemia; CALLA/CD10	Good prognosis: hyperdiploidy, t(12;21)
CML	t(9;22) Philadelphia, BCR-ABL, ↓LAP score	Imatinib responsive
CLL	Smudge cells, CD5+CD23+	Warm AIHA association
Hodgkin lymphoma	Reed–Sternberg (owl-eye) cell, CD15+CD30+	EBV (mixed cellularity); best prognosis: lymphocyte-rich
Burkitt lymphoma	"Starry-sky", t(8;14), c-MYC	EBV, jaw mass (African)
Follicular lymphoma	t(14;18), BCL-2 overexpression	Indolent
Multiple myeloma	Rouleaux, M-spike, Bence Jones protein, "punched-out" lytic lesions	CRAB, AL amyloid

Trap: Low LAP (leukocyte alkaline phosphatase) = CML; high LAP = leukemoid reaction. This single discriminator appears repeatedly.

Bleeding and coagulation

• Platelet-type bleeding (mucocutaneous, petechiae) vs coagulation-factor bleeding (haemarthrosis, deep muscle).
• Haemophilia A (factor VIII) and B (factor IX): prolonged aPTT, normal PT, normal bleeding time, X-linked.
• von Willebrand disease: most common inherited bleeding disorder; ↑aPTT, abnormal ristocetin aggregation.
• ITP: isolated thrombocytopenia, anti-GPIIb/IIIa.
• DIC vs TTP vs HUS distinctions are a recurring matching item (coagulation profile is deranged in DIC, normal in TTP/HUS).

---

Cardiovascular System (CVS)

Atherosclerosis and ischaemic heart disease

• Response-to-injury hypothesis; endothelial dysfunction → foam cells → fatty streak → fibrous plaque.
• MI evolution (a perennial timeline question):

Time after MI	Gross	Microscopy	Complication
0–4 h	None	None / wavy fibres	Arrhythmia, sudden death
4–24 h	Pallor	Coagulative necrosis, contraction bands	Arrhythmia
1–3 days	Yellow	Neutrophils	Pericarditis, arrhythmia
3–7 days	Soft, yellow centre	Macrophages, debris removal	Rupture (free wall, septum, papillary muscle)
1–2 weeks	Red-grey	Granulation tissue, neovascularisation	—
>2 months	White scar	Dense collagen	Aneurysm, mural thrombus

Trap: Rupture risk is highest at 3–7 days (weakest wall, macrophage-mediated lysis). Reperfusion injury → contraction band necrosis.

Valvular and inflammatory heart disease

• Rheumatic heart disease: Aschoff bodies (pathognomonic), Anitschkow cells ("caterpillar" nuclei), MacCallum plaques; mitral valve most affected; type II hypersensitivity (molecular mimicry, group A strep M protein).
• Infective endocarditis: Duke criteria; acute (Staph aureus, large vegetations) vs subacute (Strep viridans, damaged valves); marantic (non-bacterial thrombotic — malignancy) and Libman–Sacks (SLE).
• Cardiomyopathies: dilated (alcohol, peripartum, doxorubicin), hypertrophic (autosomal dominant β-myosin heavy chain MYH7, sudden death in athletes), restrictive (amyloid, sarcoid, endomyocardial fibrosis).
• Vasculitides (overlap with immunopathology and Medicine): Giant cell arteritis (temporal, jaw claudication, ↑ESR), Takayasu (young Asian women, pulseless), PAN (HBsAg, renal/GI, spares lung), Kawasaki (children, coronary aneurysm), Buerger (smokers, corkscrew collaterals).

---

Respiratory System

• Obstructive vs restrictive pattern logic (FEV₁/FVC) — overlap with Physiology.
• Emphysema: centriacinar (smoking, upper lobe) vs panacinar (α₁-antitrypsin deficiency, lower lobe); protease–antiprotease imbalance.
• Chronic bronchitis: Reid index > 0.4 (gland-to-wall thickness).
• Asthma: Curschmann spirals, Charcot–Leyden crystals (eosinophil-derived, galectin-10), Creola bodies.
• Pneumonia: lobar (Strep pneumoniae) stages — congestion, red hepatisation, grey hepatisation, resolution.
• Pneumoconioses: coal (anthracosis), silicosis (eggshell calcification, ↑TB risk, birefringent silica), asbestosis (ferruginous bodies, pleural plaques, mesothelioma and bronchogenic carcinoma — synergistic with smoking).
• Lung cancers: central + smoking + paraneoplastic (squamous → PTHrP/hypercalcaemia; small cell → ADH/ACTH, Lambert–Eaton); peripheral (adenocarcinoma — commonest overall and in non-smokers, EGFR/ALK; large cell).
• Pleural effusion: Light's criteria for exudate — pleural/serum protein >0.5, pleural/serum LDH >0.6, or pleural LDH > ⅔ upper-normal serum LDH.
• Sarcoidosis: non-caseating granulomas, Schaumann and asteroid bodies, ↑ACE, ↑Ca, bilateral hilar lymphadenopathy.

Trap: Charcot–Leyden crystals = asthma/eosinophils; do not confuse with Curschmann spirals (mucus plugs). Both are in asthma.

---

GIT & Liver

Gastrointestinal tract

• Barrett oesophagus → adenocarcinoma; squamous cell carcinoma of oesophagus linked to smoking, alcohol, hot beverages, achalasia.
• Gastritis & ulcers: H. pylori (most common, antral, ↑gastric cancer & MALT lymphoma), autoimmune (body/fundus, pernicious anaemia, anti-parietal/anti-IF antibodies).
• Inflammatory bowel disease — a classic comparison item:

Feature	Crohn disease	Ulcerative colitis
Distribution	Mouth to anus, skip lesions	Continuous, rectum upward
Depth	Transmural	Mucosa/submucosa
Granuloma	Non-caseating, present	Absent
Gross	Cobblestone, creeping fat, strictures, fistulae	Pseudopolyps, lead-pipe colon
Smoking	Worsens	Protective
Cancer risk	Lower	Higher
Antibody	ASCA	p-ANCA

• Colorectal carcinoma pathways: APC → KRAS → p53 (adenoma–carcinoma, chromosomal instability) vs microsatellite instability/Lynch (MLH1/MSH2). Right-sided → iron-deficiency anaemia; left-sided → obstruction.
• Polyps: hyperplastic (benign), tubular vs villous (more malignant) adenoma, FAP (APC), Peutz–Jeghers (STK11, hamartomas, mucocutaneous pigmentation).
• Appendicitis, diverticulosis, ischaemic colitis (watershed: splenic flexure, rectosigmoid).

Liver

• Jaundice classification (prehepatic/unconjugated, hepatic, posthepatic/conjugated) — overlap with Biochemistry. Gilbert (mild UGT1A1), Crigler–Najjar (severe), Dubin–Johnson (black liver, conjugated, MRP2), Rotor.
• Hepatitis: councilman bodies (apoptotic hepatocytes), ground-glass hepatocytes (HBV), serology overlap with Microbiology.
• Cirrhosis: micronodular (alcohol) vs macronodular (viral); Mallory–Denk bodies (alcohol), portal hypertension sequelae.
• Metabolic: Wilson disease (ATP7B, ↓ceruloplasmin, Kayser–Fleischer rings), haemochromatosis (HFE, "bronze diabetes", ↑transferrin saturation/ferritin), α₁-antitrypsin (PAS-positive diastase-resistant globules).
• Hepatocellular carcinoma: ↑AFP, HBV/HCV/aflatoxin (p53 mutation, codon 249).

---

Renal System

A reliably difficult, high-discrimination group — glomerular disease patterns are heavily examined.

Glomerular disease

Disease	Light microscopy	IF	EM	Clue
Minimal change	Normal	Negative	Foot process effacement	Child, steroid-responsive nephrotic
FSGS	Focal segmental sclerosis	Non-specific	Effacement	HIV, obesity; commonest nephrotic in adults
Membranous	Diffuse thickening, spike-and-dome	Granular IgG/C3	Subepithelial	Anti-PLA2R; commonest in older adults
Post-strep GN	Hypercellular	Granular ("starry sky")	Subepithelial humps	Child, 1–3 wk post-infection, ↓C3
IgA (Berger)	Mesangial proliferation	Mesangial IgA	Mesangial deposits	Synpharyngitic haematuria
Membranoproliferative	Tram-track	C3 ± Ig	Subendothelial	↓C3, C3 nephritic factor
Diabetic	Kimmelstiel–Wilson nodules	—	GBM thickening	Most common cause of ESRD
Lupus nephritis	Wire-loop	"Full house"	Sub-endo/epithelial	Class IV worst
Anti-GBM/Goodpasture	Crescents	Linear IgG	—	Haemoptysis + RPGN
Alport	—	—	Basket-weave GBM	Type IV collagen, deafness

Trap: Nephrotic (heavy proteinuria >3.5 g, hypoalbuminaemia, oedema) vs nephritic (haematuria, hypertension, RBC casts, mild proteinuria). Crescents = rapidly progressive GN. Memorise the IF pattern — it is the single most discriminating fact.

Tubulointerstitial and others

• Acute tubular necrosis: muddy-brown granular casts; ischaemic vs nephrotoxic.
• AKI definitions: RIFLE / AKIN / KDIGO staging by creatinine and urine output.
• Renal cell carcinoma: clear cell (most common, VHL, chromosome 3p), paraneoplastic (EPO → polycythaemia), "cannonball" lung mets.
• Wilms tumour (nephroblastoma): child, WT1, triphasic; Urothelial carcinoma (bladder, smoking, aniline dyes, schistosomiasis → SCC).

---

Endocrine Pathology

• Thyroid:
  • Hashimoto — Hürthle cells, lymphocytic infiltrate, anti-TPO/anti-thyroglobulin, risk of lymphoma.
  • Graves — diffuse hyperplasia, TSI antibody.
  • Papillary carcinoma — commonest, Orphan-Annie nuclei, psammoma bodies, nuclear grooves, lymphatic spread, BRAF/RET, best prognosis.
  • Follicular — haematogenous spread, capsular/vascular invasion needed for diagnosis.
  • Medullary — calcitonin, amyloid stroma, RET, MEN 2.
  • Anaplastic — elderly, worst prognosis.
• Adrenal: Cushing, Conn, phaeochromocytoma (rule of 10s; chromaffin, ↑metanephrines), neuroblastoma (children, N-MYC, Homer-Wright rosettes, ↑VMA/HVA).
• MEN syndromes: MEN1 (3 P's — pituitary, parathyroid, pancreas; MEN1/menin), MEN2A/2B (RET; medullary thyroid + phaeo ± parathyroid / mucosal neuromas + marfanoid).
• Diabetes: type 1 (autoimmune, anti-GAD, insulitis, HLA-DR3/DR4), type 2 (amylin/islet amyloid, insulin resistance); complications overlap with renal, CVS, ophthalmology.
• Pancreatic endocrine tumours: insulinoma (Whipple triad), gastrinoma (Zollinger–Ellison), VIPoma, glucagonoma.

---

Central Nervous System (CNS)

• Neurodegeneration (overlap with Medicine/Psychiatry):
  • Alzheimer — neuritic plaques (β-amyloid), neurofibrillary tangles (hyperphosphorylated tau), hippocampal atrophy, ApoE4.
  • Parkinson — Lewy bodies (α-synuclein), loss of substantia nigra dopaminergic neurons.
  • Huntington — caudate atrophy, CAG repeats.
  • ALS, Pick disease, prion (spongiform, PrP).
• CNS tumours: astrocytoma/glioblastoma (pseudopalisading necrosis, IDH/MGMT now in molecular grading), oligodendroglioma (fried-egg, 1p/19q codeletion), meningioma (psammoma bodies, women), medulloblastoma (child, cerebellum, Homer-Wright rosettes), ependymoma, schwannoma (Antoni A/B, NF2, S100+), retinoblastoma (RB1, Flexner–Wintersteiner rosettes).
• Cerebrovascular: red (haemorrhagic) vs pale infarcts; liquefactive necrosis; Charcot–Bouchard microaneurysms (hypertensive bleed, basal ganglia); berry aneurysm rupture (subarachnoid haemorrhage, ADPKD association).
• Demyelination: multiple sclerosis (periventricular plaques, oligoclonal bands).

---

Neoplasia

The conceptual capstone — increasingly the most heavily weighted single group in INI-CET because it integrates molecular biology, IHC and clinical oncology.

Core concepts

• Hallmarks of cancer (self-sufficiency in growth signals, evasion of apoptosis, limitless replication, angiogenesis, invasion/metastasis, immune evasion, altered metabolism — Warburg effect).
• Oncogenes vs tumour suppressors: RAS, MYC, HER2/neu, ABL (gain-of-function, dominant) vs RB, p53 ("guardian of the genome"), APC, BRCA1/2, VHL, NF1/2 (loss-of-function, two-hit Knudson hypothesis).
• Grading (differentiation) vs staging (TNM, extent) — staging matters more for prognosis.
• Carcinogens: aflatoxin (HCC), vinyl chloride (angiosarcoma), benzene (leukaemia), aniline dyes (bladder), HPV 16/18 (cervical — E6/E7 inactivate p53/Rb), EBV (Burkitt, nasopharyngeal, Hodgkin), HBV/HCV, H. pylori.

Tumour markers and IHC (extremely high-yield)

Marker	Tumour
AFP	HCC, yolk sac (endodermal sinus) tumour
CEA	Colorectal (monitoring, not screening)
CA-125	Ovarian (epithelial)
CA 19-9	Pancreatic
PSA	Prostate
β-hCG	Choriocarcinoma, gestational trophoblastic disease
Chromogranin/Synaptophysin	Neuroendocrine tumours
S-100	Melanoma, schwannoma, Langerhans cells
Cytokeratin	Carcinomas (epithelial)
Vimentin	Sarcomas (mesenchymal)
Desmin	Muscle tumours
CD45 (LCA)	Lymphomas
CD31 / Factor VIII	Vascular tumours
HMB-45	Melanoma
TdT	Lymphoblastic (ALL)
Calcitonin	Medullary thyroid carcinoma

Trap: Tumour markers are for monitoring and follow-up, not primary screening (except limited roles). PSA "screening" controversy is a recurrent statement-based item.

---

Cross-Subject Integration Points

Pathology is rarely tested in isolation; the highest-yield questions live at the seams between subjects.

• Pathology ↔ Biochemistry: jaundice/bilirubin metabolism, lysosomal storage diseases, glycogen storage, free radicals/antioxidants, tumour metabolism (Warburg).
• Pathology ↔ Microbiology: granulomatous infections (TB, leprosy, fungi), hepatitis serology, oncogenic viruses, H. pylori, opportunistic infections in immunosuppression.
• Pathology ↔ Pharmacology: anti-TNF and TB reactivation, chemotherapy mechanisms, anticoagulant monitoring (PT/INR vs aPTT), ATRA in APL, imatinib in CML.
• Pathology ↔ Medicine: autoantibody panels, anaemia work-up, glomerulonephritis, vasculitis, leukaemia/lymphoma management.
• Pathology ↔ OBG: gestational trophoblastic disease (β-hCG), ovarian and cervical neoplasia, breast pathology (ER/PR/HER2 — defines treatment).
• Pathology ↔ Forensic/Community Medicine: screening test principles (sensitivity/specificity), occupational lung disease.

---

Recent Update Themes (Current-Exam Relevant)

Examiners increasingly reward candidates who know that diagnosis and classification have moved from morphology toward molecular and immunohistochemical criteria.

• WHO molecular classifications: CNS tumours now graded with IDH mutation, 1p/19q codeletion, MGMT status; haematolymphoid tumours classified by recurrent genetic abnormalities; thyroid and renal tumour reclassifications (e.g., NIFTP replacing "non-invasive follicular variant papillary carcinoma").
• Targeted-therapy markers: EGFR/ALK/ROS1/PD-L1 in lung adenocarcinoma; HER2 in breast/gastric; BRAF in melanoma/thyroid — each ties an IHC/molecular result to a drug.
• Anti-PLA2R as the marker of primary membranous nephropathy.
• Liquid biopsy / circulating tumour DNA as an emerging concept item.
• Updated CKD/AKI staging (KDIGO) and NAFLD/MAFLD terminology in liver pathology.
• Immune checkpoint biology (PD-1/PD-L1, CTLA-4) — increasingly examined as the mechanism behind modern immunotherapy.

For an exam, the safe approach is: know the classic morphology first, then layer the defining molecular marker on top.

---

Study Roadmap

Phase 1 — Foundation (build the spine)

Start with General Pathology completely before any system. Cell injury, inflammation, healing, haemodynamics, immunopathology and neoplasia core form the grammar of every later chapter. Pair this with your Haematology reading because smear morphology appears everywhere.

Phase 2 — Systemic integration

Cover the systemic groups in parallel with the corresponding clinical subject (renal pathology with nephrology, cardiac pathology with cardiology). This doubles retention because you encode mechanism and management together. Make a personal table notebook for: anaemia cut-offs, glomerular IF patterns, tumour markers, IHC, translocations.

Phase 3 — Image and association drilling

Pathology rank is won on pattern recognition. Do daily image decks: gross specimens, smears, histology slides, special stains. Convert every "buzzword ↔ disease" into active recall flashcards.

Phase 4 — Integrated MCQ practice

Solve previous-year questions subject-wise first, then in mixed grand tests. Log every wrong answer with the one-line reason in your error notebook; review weekly.

Last-week revision strategy

• Revise only your own tables and error notebook — not fresh textbook.
• One fast pass each of: necrosis types, inflammation mediators, anaemia/leukaemia chart, glomerular IF table, tumour markers/IHC, gene–disease list, MI timeline.
• Spend the final 48 hours on high-yield association lists and images — these convert directly into marks with minimal effort.
• Do not start new topics; consolidate. Sleep and a calm grand-test rhythm protect your accuracy more than cramming.

---

High-Yield Mnemonics

• Inflammation cardinal signs: Rubor, Tumor, Calor, Dolor, Functio laesa.
• Caseous = TB; Liquefactive = brain abscess.
• MI rupture window: "3-to-7, weakest of heaven" (3–7 days, macrophage phase).
• MEN1 = 3 P's (Pituitary, Parathyroid, Pancreas). MEN2 = RET.
• Crohn = "skip, transmural, granuloma, cobblestone"; UC = "continuous, mucosal, pseudopolyp, cancer."
• Light's criteria → exudate if Protein ratio >0.5 or LDH ratio >0.6 ("Pleural Loves to Exude").
• B12 → both MMA and homocysteine up; folate → only homocysteine up.
• Knudson "two-hit" for tumour suppressors (RB, p53).

---

Rapid-Fire One-Liners

1. Apple-green birefringence on Congo red = amyloidosis.
2. Auer rods = AML; smudge cells = CLL; Reed–Sternberg cell = Hodgkin lymphoma.
3. t(9;22) Philadelphia / BCR-ABL = CML; low LAP score confirms it.
4. Most common cause of ESRD in India = diabetic nephropathy (Kimmelstiel–Wilson nodules).
5. Anti-PLA2R = primary membranous nephropathy; linear IgG = anti-GBM/Goodpasture.
6. Psammoma bodies = papillary thyroid CA, meningioma, serous ovarian CA, mesothelioma.
7. Subepithelial humps = post-streptococcal GN; spike-and-dome = membranous.
8. HbA₂ raised = β-thalassaemia trait; target cells = thalassaemia, liver disease, iron deficiency.
9. Schistocytes + thrombocytopenia + normal coagulation = TTP/HUS; deranged coagulation = DIC.
10. PTHrP from squamous cell lung carcinoma → hypercalcaemia; ADH/ACTH → small cell.
11. Ferritin is the single most specific test for iron deficiency (but is an acute-phase reactant).
12. p53 = guardian of the genome; most commonly mutated gene in human cancer.

---

Pathology rewards structured, association-rich learning more than any other paraclinical subject. Build the General Pathology and Haematology foundation early, learn each system as a small set of defining morphologies plus their molecular markers, drill images relentlessly, and revise from your own condensed tables in the final week. Do this and Pathology becomes the most reliable, highest-return block of marks in your entire NEET PG / INI-CET attempt.